Centre asks Serum Institute and Bharat Biotech to lower prices of COVID-19 vaccines

The decision comes after many state governments have objected to different prices of the vaccines, with Delhi Chief Minister Arvind Kejriwal saying this is not time for 'profiteering'

Press Trust of India April 26, 2021 20:56:31 IST
Centre asks Serum Institute and Bharat Biotech to lower prices of COVID-19 vaccines

Representational image. AP

New Delhi: The central government on Monday asked the Serum Institute and Bharat Biotech to lower the prices of their COVID-19 vaccines amid criticism from various states who objected to profiteering during such a major crisis.

The issue of vaccine pricing was discussed at a meeting chaired by Cabinet Secretary Rajiv Gauba. Now the two companies are expected to come up with revised pricing for their vaccines.

The Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals.

The Pune-based Serum Institute of India (SII), the world's largest vaccine maker in terms of volume, has announced a price of Rs 400 per dose for its COVID-19 vaccine, 'Covishield', for state governments and Rs 600 per dose for private hospitals.

Both vaccines are available to the central government at a rate of Rs 150 per dose.

Many states have objected to different prices of the vaccines, with Delhi Chief Minister Arvind Kejriwal saying this is not time for profiteering.

India has announced the expansion of its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.

Updated Date:

also read

Covishield produced more antibodies than Covaxin, finds preliminary study
India

Covishield produced more antibodies than Covaxin, finds preliminary study

The study, which is a preprint and has not been peer-reviewed, should not be used to guide clinical practice. However, it claimed that seropositivity rates to anti-spike antibodies were significantly higher in Covishield recipients

Delta variant of COVID-19 can infect despite Covishield, Covaxin doses, claims preliminary AIIMS study
India

Delta variant of COVID-19 can infect despite Covishield, Covaxin doses, claims preliminary AIIMS study

The study included 63 people who got breakthrough infections; of which 36 patients received two doses, while 27 had received one dose of vaccine

Serum Institute of India gets DCGI's nod to manufacture Sputnik V in India for test, analysis
India

Serum Institute of India gets DCGI's nod to manufacture Sputnik V in India for test, analysis

The Pune-based firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology in Moscow for developing Sputnik V at its licensed Hadapsar facility